Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023061 · ClinicalTrials.gov registry record · Phase 2
Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01023061 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 24 participants.
The verdict
NCT01023061, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate, leuprolide acetate, and goserelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving abiraterone acetate and leuprolide acetate or goserelin before or together with radiation therapy may be an effective treatment for prostate cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG abiraterone acetate
- DRUG prednisone
- DRUG leuprolide acetate
- RADIATION external beam radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023061
The ClinicalTrials.gov registry entry for NCT01023061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01023061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01023061 about?
NCT01023061 is a clinical study titled "Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer". This phase II trial studies the side effects and how well abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy works in treating patients with localized or locally advanced prostate cancer. Androgens can cause the growth of prostate cancer cells. A...
What is the current status of trial NCT01023061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01023061?
The interventions under investigation include: laboratory biomarker analysis (OTHER), abiraterone acetate (DRUG), prednisone (DRUG), leuprolide acetate (DRUG), external beam radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01023061?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.